US/UK/Canada

Share

Contacts

  • Orexo
    Box 303 751 05 Uppsala
    +46 (0)18 780 88 00
    +46 (0)18 780 88 88
    http://www.orexo.com

    • Quotes

    With the acquisition of the rights to two digital health products from GAIA and the appointment of Dennis, a thought leader in the digital health industry in the US, we are well positioned to lead this development within the complementary disease areas of our pharmaceutical business.
    Nikolaj Sørensen, President and CEO
    Our strategy is to focus on solutions with scientifically proven therapeutic effect which will benefit the healthcare system as a whole and more importantly patients.
    Nikolaj Sørensen, CEO, about Digital Therapies
    I am convinced that DTx will become an integral and natural part of addiction treatment in the future. This digital therapy for OUD patients is perfectly positioned with Orexo’s competences and commercial organization in the US.
    Nikolaj Sørensen, President and CEO
    Mundipharma Australia has been a good partner in the approval process and we are confident that their experience and infrastructure will create a strong foundation for a successful launch of Zubsolv®
    Nikolaj Sørensen, President and CEO
    Pick a time period -
    Tags ( Active)

    Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUD

    · The digital therapeutic can be a valuable addition to clinician supervised medication-assisted treatment programs for individuals with opioid use disorder (OUD) · The study is designed to enroll an estimated 400 participants at 35 sites across the US · Orexo brings deep category expertise to the research effort, having served the US OUD market extensively over the last eight years Uppsala, Sweden – July 1, 2021 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the enrollment of the first participant in the pivotal study of digital therapeutic modia™, in combination

    Orexo starts to test modia™ on patients in collaboration with ApexB.io and Magellan Rx Management

    · The Covid-19 pandemic has highlighted the urgent need for additional resources to prevent overdose deaths, which have reached an all-time high with an increase of 21 percent[1] · The medication-assisted treatment (MAT) of opioid use disorder (OUD) requires a combination of drug and therapy treatment, where access and quality of counselling and psychosocial support are one of the main barriers to successful treatment · modia™ can help those with OUD by providing access to an evidence-based digital therapy rooted in cognitive behavioral techniques Uppsala, Sweden – February 10,

    Orexo launches deprexis® and vorvida® in the US and provides updated financial guidance

    · FDA´s “Enforcement Policy” and Orexo´s strong financial position enable investments in an accelerated commercialization of its scientifically proven digital therapies · Preliminary estimated sales potential of USD 420-650 million for the DTx portfolio five years post launch · To enable accelerated launch of all three products investments will increase and OPEX for FY 2020 is expected to be in the range of SEK 750-800 million, from SEK 550-600 million Uppsala, Sweden – July 2, 2020 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces today the US launch of the scientifically

    Orexo submits application for vorvida® to the FDA to enable commercialization in the US

    ·  vorvida® clearance from FDA anticipated Q2 2020 · expects to launch its first digital therapy in the US for heavy alcohol use in H2 2020 Uppsala, Sweden – March 6, 2020. Orexo AB (publ), today announces it has submitted an application to the US Food and Drug Administration (FDA) for vorvida® to enable commercialization in the US. vorvida®, is a digital therapy with clinically proven efficacy for the treatment of bothersome or harmful alcohol consumption including diagnosed alcohol use disorder (AUD). Subject to hearing from the FDA, which is expected during the second quarter of

    Invitation – Orexo Capital Markets Day, Stockholm, Sweden, March 17

    Uppsala, Sweden – February 19, 2020 – Orexo AB (publ.), today invites investors, analysts and media to attend the company´s Capital Markets Day, taking place in Stockholm, Sweden, onMarch 17, at Helio GT30, Grev Turegatan 30. Members of Orexo’s management team, including recently appointed EVP Digital Therapeutics, Dennis Urbaniak, will provide an update on the company´s strategy, R&D pipeline and business opportunities within digital health. Also speaking will be Dr. Mario Weiss, CEO and Founder of GAIA AG, a global leader in digital therapeutics.The agenda for the day is displayed

    Orexo appoints Dennis Urbaniak as Executive Vice President Digital Health

    · Appointment strengthens Orexo’s competencies and resources within digital health · Orexo committed to finding innovative solutions to improve treatment of addiction Uppsala, Sweden – December 2, 2019. Orexo AB (publ), the fully integrated specialty pharmaceutical company with the aim of becoming a leader within treatment of addiction, today announces it has appointed Dennis Urbaniak as Executive Vice President (EVP) of Digital Health, effective today. Dennis will lead the establishment of Orexo’s global digital health business, initially through the development of two digital

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media